Alpha-9 Oncology Begins Phase 1 Trial Dosing with A9-3202 in Melanoma Patients

Alpha-9 Oncology, a firm in the clinical trial phase focused on creating radiopharmaceuticals for global cancer treatment, recently declared the initial dosing of a participant in its Phase 1 trial. This study is investigating the effectiveness of 68Ga-A9-3202, a radiodiagnostic agent that targets the melanocortin 1 receptor (MC1R), used for the detection of either locally advanced or metastatic melanoma. It is recognized that MC1R levels are higher in cases of malignant melanoma and various other skin cancer forms.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

The initial clinical trial being conducted across multiple sites, Phase 1, focuses on studying both the absorption of 68Ga-A9-3202 by tumors and its distribution in healthy tissues in individuals diagnosed with advanced or metastatic melanoma. This innovative compound will soon be paired with standard imaging techniques such as CT or PET/CT to determine which patients are candidates for a new radiotherapeutic targeting MC1R, also created by Alpha-9.

Dr. Ovid Trifan, Chief Medical Officer at Alpha-9 elaborated, “The introduction of this compound signifies the beginning of our mission to create targeted radiopharmaceutical therapies for treating patients afflicted with advanced or metastatic melanoma. We are enthusiastic about progressing these molecules in the clinical pathway."

Alpha-9 Oncology, engaged in the clinical phase of development, specializes in crafting distinct, highly targeted radiopharmaceuticals designed to enhance cancer treatment significantly. Using unique technologies and profound expertise, Alpha-9 is spearheading the development of custom radiopharmaceuticals. These are finely tuned to deliver radiation selectively to cancer cells, thus limiting impacts on healthy tissues. With a strong emphasis on methodical molecule design, Alpha-9 is propelling a promising selection of novel radiopharmaceuticals and exploring numerous established cancer targets.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of May 9, 2024, there are 21 investigational drugs for the MC1R target, including 62 indications, 24 R&D institutions involved, with related clinical trials reaching 88, and as many as 2964 patents.

A9-3202 is a radionuclide drug conjugate and therapeutic radiopharmaceutical that targets MC1R. It is primarily used in the treatment of neoplasms, including metastatic melanoma and melanoma. The drug is developed by Alpha-9 Oncology, Inc. and has reached Phase 1 of development. Further research and clinical trials will be necessary to determine its efficacy and potential for commercialization.